Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, has announced it will invest in additional drug product manufacturing capabilities in Switzerland
All drug substance for Moderna’s authorized Spikevax (COVID-19 mRNA vaccine) targeting the SARS-CoV-2 LP.8.1 variant is produced at the company’s facility in Laval, Quebec
Maria Soler Nunez appointed as Chief Quality Officer
The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age
This authorization follows FDA approval in June and WHO’s July recommendation adding twice-yearly lenacapavir as a PrEP option
All 2025 pre-filled syringe doses to be made in Canada, marking a domestic production milestone
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Takara Bio Europe will distribute MN’s Bioanalysis portfolio in Austria, Belgium, Denmark, France, Germany, Ireland, Luxembourg, Sweden, Switzerland, and the United Kingdom
Friesland Campina Professional’s innovative Kievit portfolio features fat powders, creamers, foamers, whipping agents, cake emulsifiers
Subscribe To Our Newsletter & Stay Updated
